Zymeworks BC Inc. (ZYME) NASDAQ
$8.86 (0.07) (-0.78%)
Market Cap: $630.17M
As of 04/17/24 03:55 PM EDT. Market open.
Zymeworks BC Inc. (ZYME)
NASDAQ
$8.86
(0.07) (-0.78%)
Market Cap: $630.17M
As of 04/17/24 03:55 PM EDT. Market open.
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly ... read more
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com. read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Galbraith Kenneth | Chair & CEO | Jan 08, 2024 | Sale | $11.22 | 5,706 | 63,996 | 23,762 | Jan 08, 2024, 06:23 PM |
Galbraith Kenneth | Chair & CEO | Jan 05, 2024 | Sale | $10.65 | 18,198 | 193,849 | 29,468 | Jan 08, 2024, 06:23 PM |
Astle Christopher | SVP & Chief Financial Officer | Jan 05, 2024 | Sale | $10.65 | 4,563 | 48,606 | 7,934 | Jan 08, 2024, 06:14 PM |
Astle Christopher | SVP & Chief Financial Officer | Jan 08, 2024 | Sale | $11.22 | 1,431 | 16,050 | 6,503 | Jan 08, 2024, 06:14 PM |
Moore Paul Andrew | Chief Scientific Officer | Jan 08, 2024 | Sale | $11.22 | 2,339 | 26,233 | 7,367 | Jan 08, 2024, 06:01 PM |
Moore Paul Andrew | Chief Scientific Officer | Jan 05, 2024 | Sale | $10.65 | 7,460 | 79,465 | 9,706 | Jan 08, 2024, 06:01 PM |
Astle Christopher | SVP & Chief Financial Officer | Dec 11, 2023 | Sale | $9.13 | 886 | 8,089 | 1,997 | Dec 11, 2023, 08:00 PM |
EcoR1 Capital, LLC | 10% Owner | Jun 16, 2023 | Buy | $8.12 | 3,350,000 | 27,202,000 | 13,437,473 | Jun 21, 2023, 04:04 PM |
EcoR1 Capital, LLC | 10% Owner | Mar 28, 2023 | Buy | $8.00 | 200,000 | 1,600,000 | 10,087,473 | Mar 30, 2023, 05:47 PM |
Klompas Neil A | President & COO | Mar 10, 2023 | Sale | $7.83 | 2,977 | 23,298 | 17,032 | Mar 14, 2023, 05:00 PM |
EcoR1 Capital, LLC | 10% Owner | Jan 20, 2023 | Buy | $9.88 | 163,400 | 1,615,095 | 9,887,473 | Jan 23, 2023, 06:00 PM |
EcoR1 Capital, LLC | 10% Owner | Jan 19, 2023 | Buy | $9.49 | 144,100 | 1,367,639 | 9,724,073 | Jan 23, 2023, 06:00 PM |
EcoR1 Capital, LLC | 10% Owner | Jan 18, 2023 | Buy | $10.00 | 203,000 | 2,029,046 | 9,579,973 | Jan 18, 2023, 06:27 PM |
EcoR1 Capital, LLC | 10% Owner | Jan 17, 2023 | Buy | $9.80 | 440,000 | 4,313,848 | 9,376,973 | Jan 18, 2023, 06:27 PM |
EcoR1 Capital, LLC | 10% Owner | Jan 13, 2023 | Buy | $9.81 | 342,100 | 3,354,633 | 8,936,973 | Jan 18, 2023, 06:27 PM |
EcoR1 Capital, LLC | 10% Owner | Jan 10, 2023 | Buy | $7.65 | 920,000 | 7,037,172 | 8,488,573 | Jan 12, 2023, 04:47 PM |
EcoR1 Capital, LLC | 10% Owner | Jan 11, 2023 | Buy | $7.87 | 106,300 | 836,911 | 8,594,873 | Jan 12, 2023, 04:47 PM |
Astle Christopher | SVP & Chief Financial Officer | Dec 12, 2022 | Sale | $6.01 | 887 | 5,331 | 1,333 | Dec 23, 2022, 08:00 PM |
Josephson Neil | Chief Medical Officer | Nov 10, 2022 | Sale | $8.10 | 2,475 | 20,045 | 14,449 | Dec 23, 2022, 08:00 PM |
Astle Christopher | SVP & Chief Financial Officer | Dec 12, 2022 | Sale | $6.01 | 887 | 5,331 | 1,333 | Dec 14, 2022, 08:00 PM |
Josephson Neil | Chief Medical Officer | Nov 10, 2022 | Sale | $8.10 | 2,475 | 20,045 | 14,449 | Nov 14, 2022, 09:41 PM |
Redmile Group, LLC | 10% Owner | Oct 13, 2022 | Buy | $5.03 | 30,481 | 153,435 | 6,075,918 | Oct 18, 2022, 06:07 AM |
Redmile Group, LLC | 10% Owner | Oct 13, 2022 | Option Exercise | $5.03 | 30,481 | 153,435 | 6,075,918 | Oct 17, 2022, 09:48 PM |
Owner | Relationship | Date | Value($) |
Galbraith Kenneth | Chair & CEO | 01/08/2024 | 63,996 |
Galbraith Kenneth | Chair & CEO | 01/05/2024 | 193,849 |
Astle Christopher | SVP & Chief Financial Officer | 01/05/2024 | 48,606 |
Astle Christopher | SVP & Chief Financial Officer | 01/08/2024 | 16,050 |
Moore Paul Andrew | Chief Scientific Officer | 01/08/2024 | 26,233 |
Moore Paul Andrew | Chief Scientific Officer | 01/05/2024 | 79,465 |
Astle Christopher | SVP & Chief Financial Officer | 12/11/2023 | 8,089 |
EcoR1 Capital, LLC | 10% Owner | 06/16/2023 | 27,202,000 |
EcoR1 Capital, LLC | 10% Owner | 03/28/2023 | 1,600,000 |
Klompas Neil A | President & COO | 03/10/2023 | 23,298 |
EcoR1 Capital, LLC | 10% Owner | 01/20/2023 | 1,615,095 |
EcoR1 Capital, LLC | 10% Owner | 01/19/2023 | 1,367,639 |
EcoR1 Capital, LLC | 10% Owner | 01/18/2023 | 2,029,046 |
EcoR1 Capital, LLC | 10% Owner | 01/17/2023 | 4,313,848 |
EcoR1 Capital, LLC | 10% Owner | 01/13/2023 | 3,354,633 |
EcoR1 Capital, LLC | 10% Owner | 01/10/2023 | 7,037,172 |
EcoR1 Capital, LLC | 10% Owner | 01/11/2023 | 836,911 |
Astle Christopher | SVP & Chief Financial Officer | 12/12/2022 | 5,331 |
Josephson Neil | Chief Medical Officer | 11/10/2022 | 20,045 |
Astle Christopher | SVP & Chief Financial Officer | 12/12/2022 | 5,331 |
Josephson Neil | Chief Medical Officer | 11/10/2022 | 20,045 |
Redmile Group, LLC | 10% Owner | 10/13/2022 | 153,435 |
Redmile Group, LLC | 10% Owner | 10/13/2022 | 153,435 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
BLACKROCK INC. | 3,923,328 | 0.00104% | 8.41% | Other |
FARALLON CAPITAL MANAGEMENT LLC | 1,756,000 | 0.09% | -12.2% | Event Driven, Value |
AQR CAPITAL MANAGEMENT LLC | 686,190 | 0.01% | -14.19% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 639,672 | 0.0007% | 6.71% | Other |
PLATINUM INVESTMENT MANAGEMENT LTD | 409,839 | 0.17% | No change | Growth At A Reasonable Price, Value |
UBS OCONNOR LLC | 136,313 | 0.1% | -60.43% | Value |
RENAISSANCE TECHNOLOGIES LLC | 14,700 | 0.00024% | -7.3% | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View